The Power of RPA-CRISPR/Cas12a -Revolutionizing HCMV Diagnostics HCMV remains a significant clinical challenge, particularly for immunocompromised patients and neonatal care. While qPCR is the current gold standard, the need for faster, highly sensitive, and lab-independent testing has never been greater.
A recent breakthrough highlighted by Amp-Future introduces a cutting-edge detection system targeting the UL123 gene using a combination of RPA (Recombinase Polymerase Amplification) and CRISPR/Cas12a.
Why it matters:
โ
Higher Sensitivity: Outperforms conventional methods by ~20.5% in positive detection.
โ
No Lab Needed: Runs at a constant temperatureโperfect for POCT.
โ
Speed & Accuracy: Rapid amplification with the surgical precision of CRISPR.
This isn't just an upgrade; it's a leap toward making elite molecular diagnostics accessible anywhere, from clinics to the bedside.
๐ Read the tech breakdown: https://lnkd.in/gVkXKYgQ |
A recent breakthrough highlighted by Amp-Future introduces a cutting-edge detection system targeting the UL123 gene using a combination of RPA (Recombinase Polymerase Amplification) and CRISPR/Cas12a.
Why it matters:
โ Higher Sensitivity: Outperforms conventional methods by ~20.5% in positive detection.
โ No Lab Needed: Runs at a constant temperatureโperfect for POCT.
โ Speed & Accuracy: Rapid amplification with the surgical precision of CRISPR.
This isn't just an upgrade; it's a leap toward making elite molecular diagnostics accessible anywhere, from clinics to the bedside.
๐ Read the tech breakdown: https://lnkd.in/gVkXKYgQ